| Literature DB >> 35211009 |
Shuang Liu1, Qiao-Jun Jia2, Yi-Qing Peng1, Ting-Hui Feng1, Shu-Ting Hu1, Juan-E Dong1, Zong-Suo Liang1,2.
Abstract
Diabetes mellitus is a fast-growing disease with a major influence on people's quality of life. Oral hypoglycemic drugs and insulin are currently the main effective drugs in the treatment of diabetes, but chronic consumption of these drugs has certain side effects. Polysaccharides, saponins, flavonoids, and phenolics are the primary secondary metabolites isolated from the rhizomes of Polygonatum sibiricum Redouté [Asparagaceae], Polygonatum kingianum Collett & Hemsl [Asparagaceae], or Polygonatum cyrtonema Hua [Asparagaceae], which have attracted much more attention owing to their unique therapeutic role in the treatment and prevention of diabetes. However, the research on the mechanism of these three Polygonatum spp. in diabetes has not been reviewed. This review provides a summary of the research progress of three Polygonatum spp. on diabetes and its complications, reveals the potential antidiabetic mechanism of three Polygonatum spp., and discusses the effect of different processed products of three Polygonatum spp. in treating diabetes, for the sake of a thorough understanding of its effects on the prevention and treatment of diabetes and diabetes complications.Entities:
Keywords: Polygonatum; antidiabetic mechanism; diabetes; hypoglycemic; hypolipidemic
Year: 2022 PMID: 35211009 PMCID: PMC8861320 DOI: 10.3389/fphar.2022.758501
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Comparison of the major chemical constituents of three Polygonatum spp.
| Species | Polysaccharide (mg/g) | Saponin (mg/g) | Flavonoid (mg/g) | Phenol (mg/g) | References |
|---|---|---|---|---|---|
|
| 40.68∼123.58 | 0.289∼2.017 | 0.018∼0.035 | 0.013∼0.045 |
|
|
| 31.24∼140.94 | 1.303∼2.845 | 0.015∼0.030 | 0.007∼0.029 |
|
|
| 22.34∼140.94 | 0.030∼8.920 | 0.004∼0.034 | 0.007∼0.038 |
|
Flavonoids isolated from three Polygonatum spp.
| Number | Name | Source | References |
|---|---|---|---|
| Homoisoflavones | |||
| 1 | 4′,5,7-Trihydroxy-6-methyl-8-methoxy-homoisoflavanon |
|
|
| 2 | 4′,5,7-Trihydroxy-6-methyl-homoisoflavanon |
|
|
| 3 | 4′,5,7-Trihydroxy-6,8-dimethyl-homoisoflavanon |
|
|
| 4 | 4′,7-Dihydroxy-3′-methoxy-homoisoflavanon |
|
|
| 5 | 2,4,5,7-Tetrallydroxy-homoisoflvanaone |
|
|
| 6 | (3R)-5,7-Dihydroxy-8-methyl-3-(2′-hydroxy-4′-methoxybenzyl)-chroman-4-one |
|
|
| 7 | 5,7-Dihydroxy-6,8-dimethyl-3-(4′-hydroxybenzyl)-chroman-4-one |
|
|
| 8 | 5,7-Dihydroxy-6,8-dimethyl-3-(2′-methoxy-4′-hydroxybenzyl)-chroman-4-one |
|
|
| 9 | 5,7-Dihydroxy-6-methyl-3-(4′-hydroxybenzyl)-chroman-4-one |
|
|
| 10 | 5,7-Dihydroxy-8-methyl-3-(4′-hydroxybenzyl)-chroman-4-one |
|
|
| 11 | 5,7-Dihydroxy-6-methyl-3-(4′-methoxybenzyl)-chroman-4-one |
|
|
| 12 | 5,7-Dihydroxy-6,8-dimethyl-3-(4′-methoxybenzyl)-chroman-4-one |
|
|
| 13 | 5,7-Dihydroxy-3-(4′-hydroxybenzyl)-chroman-4-one |
|
|
| 14 | 5,7-Dihydroxy-6-methyl-3-(2′,4′-dihydroxybenzyl)-chroman-4-one |
|
|
| 15 | 5,7-Dihydroxy-3-(2′-hydroxy-4′-methoxybenzyl)-chroman-4-one |
|
|
| 16 | 5-Dihydroxy-7-methoxy-6,8-dimethyl-3-(2′-hydroxy-4′-methoxybenzyl)-chroman-4-one |
|
|
| 17 | 5,7-Dihydroxy-3-(4′-hydroxybenzylidene)-chroman-4-one |
|
|
| 18 | Disporopsin |
|
|
| 19 | Polygonatone H |
|
|
| Isoflavones | |||
| 20 | Tectoridin |
|
|
| 21 | 2′,7-Dihydroxy-3′,4′-dimethoxyisoflavanoside |
|
|
| 22 | 2′,7-Dihydroxy-3′,4′-dimethoxyisoflavan |
|
|
| 23 | 4′,7-Dihydroxy-3′-methoxyisoflavone |
|
|
| Chalcones | |||
| 24 | Isoliquiritigenin |
|
|
| 25 | Neoisoliquiritigenin |
|
|
| Dihydroflavones | |||
| 26 | Liquiritin |
|
|
| 27 | Liquiritigenin |
|
|
| Rosandalanes | |||
| 28 | Methylnissolin |
|
|
| Flavones | |||
| 29 | Apigenin-7-glucoside |
|
|
| 30 | Apigenin-8- |
|
|
| 31 | Kaempferol |
|
|
| 32 | Myricetin |
|
|
| 33 | Rutin |
|
|
| 34 | Kaempferol-3- |
|
|
FIGURE 1Experimental workflow in the study of Polygonatum spp. in the treatment of diabetes.
Antidiabetic properties of three Polygonatum spp. in cells and animal models.
| Species | Part of plant | Compounds | Concentration | Treatment duration | Model | Index | References |
|---|---|---|---|---|---|---|---|
|
| Rhizome | Polysaccharide | 50, 100, and 250 μg/ml | 12, 24, and 48 h | IR-3T3-L1 adipocytes | IL-1β, IL-6, and TNF-α↓; Nrf2 and HO-1↑ |
|
|
| Rhizome | Polysaccharide | 100 mg/L | 24 h | IR-HepG2 cells | IRS1/PI3K/Akt↑ |
|
|
| Rhizome | Saponin | 10, 5, 1, 0.5, and 0.1 mg/ml | 36 h | IR-HepG2 cells | Glucose consumption, HK, and PK↑ |
|
|
| Rhizome | Polysaccharide | 200, 400, and 800 mg/kg | 12 weeks | STZ-induced diabetic rats | Bax, EGF, p38, VEGF and TGF-β↓; Bcl-2↑ |
|
|
| Rhizome | Polysaccharide | 120, 240, and 480 mg/kg | 14 weeks | HFD rats | FBG, HDL-C, harmful bacteria↓; TC, TG, LDL-C, FINS, beneficial bacteria↑ |
|
|
| Rhizome | Polysaccharide | 1,190 mg/kg | 4 weeks | STZ-induced diabetic rats | FBG, HDL-C↓; TC, TG, LDL-C and TC/HDL-C↑ |
|
|
| Rhizome | Polysaccharide | 0.1 g/kg | 8 weeks | HFD rats | FBG, harmful bacteria↓; FINS, beneficial bacteria↑ |
|
|
| Rhizome | Polysaccharide | 450 and 900 mg/kg | 4 weeks | STZ-induced diabetic rats | IL-6, IL-1β↓; IRS-1↑ |
|
|
| Rhizome | Saponin | 1, 1.5, or 2 g/kg | 11 weeks | STZ-induced diabetic rats | Water consumption, food intake, blood glucose↓ body weight↑ |
|
|
| Rhizome | Saponin | 100, 200, and 300 mg/kg | 2 weeks | Alloxan-induced diabetic rats | blood glucose↓ |
|
|
| Rhizome | Saponin | 0.025 g/kg and 0.1 mg/kg | 8 weeks | STZ-induced diabetic rats | G6P↓; GLUT4, PPAR-γ↑ |
|
|
| Rhizome | Saponin | 0.025 and 0.1 g/kg | 8 weeks | HFD rats | FBG, harmful bacteria↓; FINS, beneficial bacteria↑ |
|
|
| Rhizome | Flavonoid | 50, 100, and 200 mg/kg | 10 days | Alloxan-induced diabetic rats | Alpha-amylase↓; insulin↑ |
|
|
| Rhizome | Phenolic | 25, 50, and 75 mg/kg | 8 weeks | STZ-induced diabetic rats | TC, TG, LDL-C, FFA, MDA, SOD, CAT, AST, ALT, ALP, and TGF-β1↓; HDL-C, T-AOC↑ |
|
|
| Rhizome | Polysaccharide | 200, 400, and 800 mg/kg | 12 weeks | STZ-induced DR rats | FBG, HbA1c, SOD↓; insulin, C-peptide, MDA ↑ |
|
|
| Rhizome | Polysaccharide | 0.25, 0.5, and 1 g/kg | 2 weeks | GM-induced AKI rats | NGAL, KIM-1, IL-1β, IL-6, TNF-α, and p38 MAPK↓ |
|
|
| Rhizome | Saponin | 35 and 70 mg/kg | 16 weeks | STZ-induced DN rats | Urea nitrogen, serum creatinine, Wnt4, β-catenin↓ |
|
Note. IRS, insulin receptor substrate; HK, hexokinase; PK, pyruvate kinase; PPAR-γ, peroxysome proliferator-activated receptor-gamma; FFA, fatty acid; CAT, catalase; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; T-AOC, total antioxidant capacity.
Chinese patent medicines containing Polygonatum with hypoglycemic effect in human studies.
| Drug name | Dosage/times (g) | Cases | Adverse reactions | Index | References |
|---|---|---|---|---|---|
| Jiangtang Tongmai capsule | 1.05 | 60 | — | HOMA-IS↑; HOMA-IR↓ |
|
| Tangwei capsule | 2.5 | 80 | Nausea and dizziness | FBG, 2hPG, HbA1c↓ |
|
| Tangmaikang granule | 5 | 102 | No | FPG, 2hPG, HbA1c, TG, TC, LDL-C, IL-6↓; HDL-C↑ |
|
| Qizhi Jiangtang capsule | 2.5 | 80 | No | ET-1, TXB2, BUN, SCr↓; NO↑ |
|
| Jinlida granule | 9 | 128 | Nausea, rash, and heart palpitations | FPG, 2hPG, HbA1c, TC, TG, LDL-C, IL-6, MDA, HOMA-IR↓; HDL-C, SOD, HOMA-β↑ |
|
| Jiangtangshu tablet | 1.5 | 165 | Diarrhea, constipation, and abdominal pain | HbA1c, FBG, HOMA-IR↓; GLP-1 and FINS↑ |
|
| Jiangtangjia tablet | 1.83 | 38 | — | FBG↓ |
|
Chinese patent medicine prescription containing Polygonatum with hypoglycemic effect (data from db.yaozh.com).
| Drug name | Sources of prescription | Prescription |
|---|---|---|
| Jiangtang Tongmai capsule | National Chinese patent medicine standard assembly Internal medicine Qi blood body fluid subvolume |
|
| Tangwei capsule | New drug regularization standards 71 |
|
| Tangmai Kang granule |
|
|
| Qizhi Jiangtang capsule |
|
|
| Jinlida granule |
|
|
| Jiangtang Shu Tablet | New drug regularization standards volume 88 |
|
| Jiangtang jia Tablet |
|
|
FIGURE 2Insulin signaling pathways of three Polygonatum spp. Note. mTOR, mammalian target of rapamycin; PDK1/2, 3-phosphoinositide-dependent protein kinase-1/2; GSK3, glycogen synthase kinase 3β.